Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Disclosure: This analysis draws on publicly available regulatory filings, patent databases, CDMO financial reports, and published clinical and manufacturing science literature
Novo is now a scaled pharmaceutical company
While originally approved for type 2 diabetes and cardiovascular disease, these drugs have demonstrated significant efficacy for weight loss, fueling public demand and legislative proposals to expand coverage
These drugs also improve blood sugar, blood pressure, and cholesterol, and reduce the risk of heart attacks and strokes
US$ 27.25
US$ 27.92
US$ 20.41
US$ 22.61
